強化阿托伐他汀對冠狀動脈介入治療的心肌保護作用-資料下載頁
2025-01-15 04:52本頁面
【正文】 ［9］Ellis SG, Chew D, Chan A, et al. Death following creatine kinaseMB elevation after coronary intervention: identification of an early risk period: importance of creatine kinaseMB level, pleteness of revascularization, ventricular function, and probable benefit of statin therapy［J］. Circulation，2002，106:12051210. ［10］Herrmann J, Lerman A, Baumgart D, et al. Preprocedural statin medication reduces the extent of periprocedural nonQwave myocardial infarction［J］. Circulation， 2002，106:21802183. ［11］Chan AW, Bhatt DL, Chew DP, et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention［J］.Circulation，2002，105:691696. ［12］Pasceri V, Patti G, Nusca A, et al. Randomized Trial of Atorvastatin for Reduction of Myocardial Damage During Coronary Intervention Results From the ARMYDA (Atorvastatin for Reduction of Myocardial Damage during Angioplasty) Study［J］. Circulation，2004，110:674678. ［13］Chyrchel M, Rakowski T, Rzeszutko L, et al. Effects of highdose statin administered prior to coronary angioplasty on the incidence of cardiac events in patients with acute coronary syndrome[J]. Kardiol Pol，2006，64:13571362. ［14］Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDAACS randomized trial[J]. J Am Coll Cardiol，2007，49:12721278. ［15］Chan AW, Bhatt DL, Chew DP, et al. Relation of inflammation and benefit of statins after percutaneous coronary interventions［J］. Circulation，2003，107:17501756.
公司管理相關(guān)推薦
鄂ICP備17016276號-1